Forum Flyer - English (pdf)
Forum Flyer - Japanese (pdf)
From the birthplace of the biotechnology revolution here in the San Francisco Bay Area, this forum will give us an outward looking perspective on the prospects for the industry in a global context. The panel will collectively address the following questions: How have the economic crisis and aftermath changed the way people do business in the biotech industry? How is the emerging market impacting the developed one? What are the notable cross border transactions? What is the key to survival/success in today’s global economy? Which local government has notable/smart initiatives? What can we learn from these initiatives?
Dr. Akiko Futamura will start the panel discussion by giving an overview of today’s global biotech industry. She will also talk about the challenges faced by the biotech companies and what they do to survive and succeed. Dr. Roger Wyse will give an overview and discuss the use of biotechnology in meeting our world’s ever increasing demand for food and energy. As the human population continues to increase rapidly, meeting this demand has become one of the most important, and often contentious, geopolitical and economical priorities in the 21st century. Dr. Wyse will talk about how industrial applications, global food security and sustainability evolve in the biotech industry. His advisory role to local government and broad investment experience will give us a fresh perspective on how governments along with private sectors intend to not only meet the aforementioned demands, but also leap ahead and become leaders in the industry. On a corporate level, Dr. Mary Haak-Frendscho will talk about how major biotech and biopharmaceutical companies are strategizing to survive this global economic downturn and position themselves for strong future growth. She will discuss the prospect for biotech research & development (R&D) and whether US is still the global leader in biotech R&D and/or manufacturing. She will also discuss how innovation and management are practiced across borders and how these practices influence the survival/success of the companies. Mr. Haru Morita will talk about his extensive experiences and the various risks/opportunities that await us in biotech startups as the industry recovers from the recession. In addition, he will discuss the benefits a foreign biotech startup may enjoy operating in the US versus elsewhere in terms of market opportunity and regulatory process.
This year the theme of Keizai Society is “Catch the Next Wave – New Opportunities for 2010”.
This forum helps us better understand the present global biotech industry and its future prospects so that we can catch the next wave, and latch on to new opportunities in the years to come. Please bring many business cards in order to exchange with attendees and panelists, since it is important to network and help each other in these tough times. And please forward this message to your friends and colleagues to expand the power of the Next Wave.
Dr. Roger Wyse is a Managing Director and General Partner at Burrill & Company, a leading Life Sciences company with $1 billion in venture capital under management, with businesses in merchant banking, private equity and media. Dr. Wyse joined Burrill in 1998 and has led the development of Burrill & Company’s agriculture, nutraceuticals, health & wellness, and industrial biotechnology related activities in venture capital investing. In this endeavor he pioneered the “Virtual Corporate Venture” model and has attracted over 40 corporate investors into the various Burrill funds. Dr Wyse chairs or serves on the boards of 11 private companies. He is Co-Chairman of the $150M Malaysian Life Capital Fund and is a member of the International Advisory Panel for Biotechnology (BioIAP) for the Prime Minister of Malaysia. He was founder and Chairman of the Alliance for Animal Genome Research. He serves on the Board of Industrial Section of BIO. Dr. Wyse is a sought after speaker on biotechnology applications and policy in food, agricultural and bio-clean-technology. He has over 30 years of experience as an internationally recognized scientist and as a Dean at two major research universities; Rutgers and the University of Wisconsin-Madison. Immediately prior to joining Burrill & Company, Dr. Wyse served for 5 years as Dean of the College of Agricultural and Life Sciences at the University of Wisconsin-Madison. From 1986 – 1992, he served as Dean of Research at Rutgers University. In research, Dr. Wyse earned international recognition for his basic studies in plant biochemistry. He published over 150 scientific papers. In recognition of his research accomplishments he received the prestigious Arthur Flemming Award in 1982 as the Outstanding Young Scientist in the US Federal Service. He was elected a Fellow of the American Association for the Advancement of Science, the Crop Science Society of America and The American Society of Agronomy. He also served as a consultant to numerous Fortune 500 companies.
Dr. Mary Haak-Frendscho is President and Chief Scientific Officer of Takeda San Francisco. She established Takeda's new center of excellence for biologics, which also serves as the therapeutic antibody (Ab) IND engine for Takeda Pharmaceutical Company, Japan’s largest biopharmaceutical and biotech company. Dr. Haak-Frendscho leads the overall Ab target discovery, Ab drug discovery, and preclinical development activities for oncology, inflammatory and metabolic candidate medicines. In addition, she is responsible for actively expanding Takeda's US science, business, and intellectual property presence in the Biotech sector. Dr. Haak- Frendscho has nearly 20 years of industry experience at companies including Genentech, Abgenix and XOMA. She is an inventor on over 25 issued and pending patents, authored about 70 scientific articles, and has an adjunct appointment at the University of Wisconsin where she obtained her PhD.
Dr. Akiko Futamura is President and CEO of InfiniteBio. Formerly, she was Executive Vice President, Science and Technology/Business Development at SC BioScience USA, a subsidiary of Sumitomo Corporation, and Vice President, Science and Technology at Summit Biotech, a venture capital arm of Sumitomo Corporation. She was responsible for identifying key technologies, conducting due diligence and was involved in business development at therapeutics and platform (tool) companies. She played a key role in concluding a number of important alliances and investments with companies such as Morphotek, Cyntellect, QuantumDot Corporation, Xenogen, Panomics and Multispan. At InfiniteBio, Dr. Futamura has assisted numerous Japanese companies commercialize novel in vitro and in vivo technologies in the U.S., including PhoenixBio, SCIVAX Corporation, and ReproCELL. Dr. Futamura received her BS in biotechnology from the University of Tokyo, and Ph.D. in biochemistry from the University of Illinois.
She is currently serving as a visiting professor at Osaka University, Japan, and is working to transfer novel technologies from Japan to the U.S. Dr. Futamura is a co-founder of the Japanese Scientists Network in the U.S.
Mr. Haru Morita has served as President, CEO and Director of REGiMMUNE, which is headquartered in Japan but has a US subsidiary in Mountain View, California. Mr. Morita has been with REGiMMUNE since founding it in 2006 and has raised over US$20 million two years ago. Prior to REGiMMUNE, Mr. Morita served on the management teams of Y's Therapeutics, Ltd. and Y's Therapeutics, Inc., most recently as Director of Business Development with responsibility for corporate planning as well. Mr. Morita's professional experience also includes management consulting at Booz Allen and Hamilton (Tokyo office). In this capacity as consultant, he helped clients to establish and implement strategy not only in pharmaceutical business but also in other area such as chemical and consumer products. Prior to that, Mr. Morita worked as a research scientist in the medical research division of Kirin Brewery Co. Ltd (lately it merged into Kyowa-Hakko-Kirin). At Kirin he was part of the research and development team that was first to clone Megakaryocyte Growth and Differentiation Factor (MDGF or Thrombopoietin). Mr. Morita received both of his BS in Chemical Engineering and MS in Molecular and Cellular Biology from the University of Tokyo.
Keizai Silicon Valley (http://keizai.org) is a Silicon Valley based business and professional networking organization. One of its primary purposes is to provide a venue of programs that showcase specialists with expertise on issues critical to the success of entrepreneurs and companies doing business with Japan and the U.S.
In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.